Please reload

Geom Therapeutics is a biotechnology company focused on the development of novel antibiotics for multidrug-resistant Gram-negative infections 

Geom Therapeutics is a privately held biopharmaceutical company focused on the development of novel antibiotics for MDR Gram-negative infections.  Geom is a joint venture with LegoChem Biosciences, a publicly traded Korean biotechnology company (KOSDAQ:141080) and the inventor of GT-1.   GT-1, our lead product candidate, a cephalosporin with a novel uptake mechanism, has demonstrated broad spectrum efficacy against Gram-negative pathogens.  We are developing GT-1 for serious bacterial infections, including those caused by MDR P. aeruginosa and Acinetobacter spp.  We have built an exceptional research and development team with deep expertise in the development of new antibiotics from discovery through approval.  Our mission is to improve patients’ lives by developing novel antibiotics to treat resistant infections for which there are no available therapies. 

GT-1 is a highly differentiated antibiotic that provides broad spectrum coverage, including activity against multi-drug resistant Pseudomonas and Acinetobacter


Pseudomonas aeruginosa

Acinetobacter baumannii


Site map:

Contact Us